marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Company profile
Ticker
MRNS
Exchange
Website
CEO
Scott N. Braunstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MARINUS PHARMACEUTICALS INC
SEC CIK
MRNS stock data
Latest filings (excl ownership)
8-K
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
15 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
8-K
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
27 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
5 Mar 24
8-K
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
4 Jan 24
8-K
Other Events
28 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
7 Nov 23
Transcripts
MRNS
Earnings call transcript
2023 Q4
5 Mar 24
MRNS
Earnings call transcript
2023 Q3
7 Nov 23
MRNS
Earnings call transcript
2023 Q2
10 Aug 23
MRNS
Earnings call transcript
2023 Q1
11 May 23
MRNS
Earnings call transcript
2022 Q4
7 Mar 23
MRNS
Earnings call transcript
2022 Q3
8 Nov 22
MRNS
Earnings call transcript
2022 Q2
11 Aug 22
MRNS
Earnings call transcript
2022 Q1
13 May 22
MRNS
Earnings call transcript
2021 Q4
21 Mar 22
MRNS
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
SC 13G
TANG CAPITAL PARTNERS LP
19 Apr 24
4
Scott Braunstein
27 Mar 24
4
Christina Shafer
22 Feb 24
4
MARTHA E MANNING
22 Feb 24
4
Joseph Hulihan
21 Feb 24
4
Steven Pfanstiel
21 Feb 24
4
Scott Braunstein
21 Feb 24
SC 13G/A
Lion Point Capital, LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 140.44 mm | 140.44 mm | 140.44 mm | 140.44 mm | 140.44 mm | 140.44 mm |
Cash burn (monthly) | (no burn) | 2.32 mm | 10.99 mm | 11.15 mm | 8.39 mm | 9.41 mm |
Cash used (since last report) | n/a | 15.87 mm | 75.26 mm | 76.38 mm | 57.46 mm | 64.44 mm |
Cash remaining | n/a | 124.57 mm | 65.18 mm | 64.06 mm | 82.98 mm | 76.00 mm |
Runway (months of cash) | n/a | 53.7 | 5.9 | 5.7 | 9.9 | 8.1 |
Institutional ownership, Q3 2023
98.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 17 |
Closed positions | 21 |
Increased positions | 41 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 410.75 bn |
Total shares | 54.13 mm |
Total puts | 174.20 k |
Total calls | 1.35 mm |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Suvretta Capital Management | 5.20 mm | $41.90 bn |
Eventide Asset Managment | 4.53 mm | $36.47 bn |
BLK Blackrock | 4.15 mm | $33.37 bn |
BEN Franklin Resources | 3.78 mm | $30.46 bn |
Avoro Capital Advisors | 3.15 mm | $25.36 bn |
Jennison Associates | 2.96 mm | $23.79 bn |
Adage Capital Partners GP, L.L.C. | 2.90 mm | $23.38 bn |
Cormorant Asset Management | 2.63 mm | $21.13 bn |
Vanguard | 2.58 mm | $20.75 bn |
Lion Point Capital | 2.15 mm | $17.27 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Braunstein Scott | Common Stock | Option exercise | Acquire M | No | No | 4.28 | 50,000 | 214.00 k | 273,512 |
27 Mar 24 | Braunstein Scott | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.28 | 50,000 | 214.00 k | 200,000 |
20 Feb 24 | Christina Shafer | Common Stock | Sell | Dispose S | No | Yes | 9.56 | 2,153 | 20.58 k | 60,308 |
20 Feb 24 | Manning Martha E | Common Stock | Sell | Dispose S | No | Yes | 9.57 | 1,894 | 18.13 k | 52,966 |
18 Jan 24 | Braunstein Scott | Common Stock | Grant | Acquire A | No | No | 0 | 74,600 | 0.00 | 235,362 |
18 Jan 24 | Braunstein Scott | Stock Option Common Stock | Grant | Acquire A | No | No | 9.74 | 335,650 | 3.27 mm | 335,650 |
18 Jan 24 | Joseph Hulihan | Common Stock | Grant | Acquire A | No | No | 0 | 21,835 | 0.00 | 69,449 |
18 Jan 24 | Joseph Hulihan | Stock Option Common Stock | Grant | Acquire A | No | No | 9.74 | 98,250 | 956.96 k | 98,250 |
News
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
17 Apr 24
RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
17 Apr 24
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
16 Apr 24
The Latest Analyst Ratings For Marinus Pharma
16 Apr 24
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
16 Apr 24
Press releases
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
15 Apr 24
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
15 Apr 24
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
5 Apr 24
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review
27 Mar 24
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
5 Mar 24